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Introduction
Heparan sulfate proteoglycans (HSPGs) comprise a complex and heterogeneous family of macromolecules that are preferentially located at the cell surface and basement membrane ( Whitelock and Iozzo, 2005; Knox and Whitelock, 2006 ; Bishop et al., 2007 ) . Perlecan, an archetypal HSPG with a large multivalent protein core, regulates basement membrane assembly, vascular and cartilage development, and tumor growth and angiogenesis ( Mathiak et al., 1997 ; Iozzo, 1998 ; Iozzo and San Antonio, 2001 ; Hassell et al., 2002 ) . The biology of perlecan extends far beyond the original notion as an anionic fi lter. This complex molecule has a variety of roles: perlecan is a structural constituent of basement membranes and is a key regulator of several growth factor signaling pathways and lipid metabolism ( Fuki et al., 2000 ; Iozzo, 2005 ; Lindner et al., 2007 ) . Moreover, although as a parent molecule, perlecan is proangiogenic ( Aviezer et al., 1994 ; Sharma et al., 1998 ; Iozzo and San Antonio, 2001 ), a C-terminal perlecan fragment named endorepellin has antiangiogenic activity in tumor xenograft models ( Mongiat et al., 2003 ; Bix et al., 2004 Bix et al., , 2006 Woodall et al., 2008 ) . Proteomic profi ling of endorepellin-targeted action on the endothelium has recently identifi ed fi ve key proteins involved with endorepellin angiostatic activity ( Zoeller and Iozzo, 2008 ) .
The multiple developmental roles of perlecan are diffi cult to dissect in placental animals because disruption of the perlecan gene leads to embryonic lethality ( Arikawa-Hirasawa et al., 1999 ; Costell et al., 1999 ) . Nearly half of the perlecan-null mice die at embryonic days 10 -12 because of hemorrhage within the pericardial cavity ( Costell et al., 1999 ) . The animals that survive exhibit severe cephalic and cartilage abnormalities and die of respiratory failure just after birth ( Arikawa-Hirasawa et al., 1999 ) . The phenotype of perlecan-null animals is quite complex in so far as a close analysis of all of the embryos that reach later stages of development show malformations of the cardiac outfl ow tract, including transposition of the great vessels and abnormal coronary artery development ( Costell et al., 2002 ; Gonz á lez-Iriarte et al., 2003 ) . A viable mutant animal has been generated in which mice lack perlecan exon 3, which contains two of the three possible heparan sulfate attachment sites ( Rossi et al., 2003 ) . Interestingly, the animals are viable and fertile but have small eyes and show degeneration of the lens within 3 wk of birth ( Rossi et al., 2003 ) . Various experimental challenges of P erlecan ' s developmental functions are diffi cult to dissect in placental animals because perlecan disruption is embryonic lethal. In contrast to mammals, cardiovascular function is not essential for early zebrafi sh development because the embryos obtain adequate oxygen by diffusion. In this study, we use targeted protein depletion coupled with protein-based rescue experiments to investigate the involvement of perlecan and its C-terminal domain V/ endorepellin in zebrafi sh development. The perlecan morphants show a severe myopathy characterized by abnormal actin fi lament orientation and disorganized sarcomeres, suggesting an involvement of perlecan in myopathies. In the perlecan morphants, primary intersegmental vessel sprouts, which develop through angiogenesis, fail to extend and show reduced protrusive activity. Live videomicroscopy confi rms the abnormal swimming pattern caused by the myopathy and anomalous head and trunk vessel circulation. The phenotype is partially rescued by microinjection of human perlecan or endorepellin. These fi ndings indicate that perlecan is essential for the integrity of somitic muscle and developmental angiogenesis and that endorepellin mediates most of these biological activities.
Results

Cloning and developmental expression of zebrafi sh perlecan
We characterized the zebrafi sh perlecan sequence by electronic PCR and cloned zebrafi sh endorepellin by RT-PCR (TPA BK006379). From a comprehensive database analysis, we conclude that zebrafi sh perlecan has an overall structure similar to the mammalian counterpart with an estimated M r of ‫ف‬ 370 kD ( Fig. 1 A ) and good conservation of domains II -V (Tables S1 and S2 , available at http://www.jcb.org/cgi/content/full/jcb.200708022/DC1). Notably, zebrafi sh perlecan lacked the fi rst 56 amino acid residues and did not contain the SGD triplets present in the mammalian counterpart where the heparan sulfate chains are attached. However, there are 14 SG dipeptides dispersed throughout domains III -V (Table S2) , with several of those conforming to the glycosaminoglycan-binding consensus found in other HSPGs ( Bishop et al., 2007 ; Wang et al., 2007 ) . Initial experiments showed that ze brafi sh perlecan is indeed an HSPG because it was completely resistant to chondroitinase ABC but was sensitive to heparitinase treatment (unpublished data). The exact domain in which the heparan sulfate chains are attached is not yet known. Moreover, nine Ig repeats were not present in zebrafi sh perlecan. Analysis of the available zebrafi sh database showed that there is one single gene encoding zebrafi sh perlecan and that it was localized to chromosome 23 syntenic to human chromosome 1 and mouse chromosome 4, where the mammalian orthologues are located ( Fig. 1 B ) . Comparative analysis of human, mouse, zebrafish, and Drosophila melanogaster domain V/endorepellin showed a high degree of conservation with ‫ف‬ 60% sequence identity and > 70% homology between human and zebrafi sh endorepellin (Fig. S1 A) . these heparan sulfate -defi cient mice result in increased stenosis in injured carotid arteries ( Tran et al., 2004 ) and impaired angiogenesis and tumor growth ( Zhou et al., 2004 ) .
In contrast to mammals, intact cardiovascular function is not essential for early zebrafi sh development because the embryos obtain adequate oxygen by simple diffusion from the environment. Morpholino-modifi ed antisense knockdown of the perlecan gene allows the morphant embryos to survive for days essentially half-way through early larval development ( ‫ف‬ 7 d postfertilization [dpf]), thereby permitting, for the fi rst time, a detailed analysis of the role of perlecan in various systems during early and late embryogenesis.
In this study, we focused on the role of perlecan in zebrafi sh muscle and cardiovascular development. The perlecan morphants showed a severe myopathy characterized by abnormal fiber orientation, reduced amounts of actin filaments, and disorganized sarcomeres, suggesting a potential role for perlecan in human myopathies. Moreover, primary intersegmental vessel (ISV) sprouts initiated but did not completely extend and showed reduced protrusive activity; often the sprouts were very thin and blunt ended and either failed to anastomose or formed irregular junctions. Live videomicroscopy confi rmed both the abnormal swimming motion caused by the muscular defects and the anomalous circulation in the head and trunk vessels. The morphant phenotype could be partially rescued by microinjection of human perlecan isolated from endothelial cells or by its C-terminal domain V/endorepellin. Collectively, our fi ndings indicate that perlecan is essential for the development and integrity of somitic muscle and developmental angiogenesis and that its C-terminal module endorepellin mediates most of these biological activities. The zebrafi sh perlecan gene ( hspg2 ) maintains a syntenic relationship with DDOST, PHC2, and SARS of mammalian species. Species and respective chromosome number are depicted; gene symbols are followed by the gene identifi cation numbers from the National Center for Biotechnology Information Entrez Gene database, and distances between genes are displayed in megabases.
PERLECAN IN MUSCLE AND VASCULAR DEVELOPMENT • ZOELLER ET AL.
1997 ) showed strong positivity at the 64-and 1,000-cell stage 2 and 3 h postfertilization (hpf; Fig. 2 , I and J ), at a time when zygotic transcription has not yet commenced, indicating that perlecan was maternally derived. At 1 -2 dpf, perlecan epitopes were detected in the head region, in the developing eyes, along the myoseptae, and at the major axial vessels ( Fig. 2, L -N ) , which is in agreement with the ISH results. The robust early embryonic expression of zebrafi sh perlecan indicates that this gene product is important for early embryogenesis.
Perlecan is essential for zebrafi sh embryonic development
To asses the developmental roles of perlecan, we selectively blocked the translation of perlecan mRNA using morpholino antisense oligonucleotides (MO), a specifi c translation inhibitor in zebrafi sh . We initially used two morpholinos of nonoverlapping sequence: one directed against the translation start site (MO-DI) of perlecan and the other encompassing the splice donor site of the initial exon of domain V/ endorepellin (MO-DV; Fig. 1 A ) . Embryos at the one-to twocell stage were injected with 2.5 -10 ng morpholino, and embryos
The BMP-1 -sensitive site that would liberate the last globular domain of endorepellin, LG3, was perfectly conserved among human, mouse, and zebrafi sh, further stressing the potential biological signifi cance of this protease-sensitive site ( Gonzalez et al., 2005 ) . Phylogenetic analysis of endorepellin from 13 separate species (Fig. S1 B) indicates that zebrafi sh and mammalian endorepellin evolved from a common ancestor.
To determine the spatiotemporal expression of zebrafi sh perlecan , we used whole mount in situ hybridization (ISH) and immunohistochemistry. ISH using a domain V antisense RNA probe showed the prominent expression of perlecan at the 20-somite stage in the head and somite region ( Fig. 2, A and B ) . Perlecan was more clearly expressed at 1 dpf in these regions and was localized along the lateral myotomes ( Fig. 2 C ) and in the major axial vessels ( Fig. 2 D ) . At 5 dpf, perlecan was expressed in the head and intestinal organs, with strong positivity in the axial vessels, including the dorsal aorta (DA) and the dorsal longitudinal anastomotic vessel (DLAV) as well as in the myoseptae, the ISVs, and posterior cardinal vein (PCV; Fig. 2 , F and G ).
Whole mount immunohistochemistry using an affi nitypurifi ed rabbit anti -mouse perlecan antibody ( Handler et al., . Perlecan mRNA can be detected at the 20-somite stage in regions of the developing brain (A) and along both sides of the notochord (B, arrows). At 1 dpf, perlecan expression is seen in the head region (C), in the developing somites (C, black arrows), and within the developing axial vasculature (D, arrows). Also note perlecan expression localized within the duct of Cuvier (C, red arrows). By 5 dpf (F and G [magnifi ed image of the region boxed in F]), perlecan expression signifi cantly increases throughout the trunk musculature (G, arrows), the major trunk/tail vessels including the DLAV, DA, and PCV, and in the developing gastrointestinal tract and future fi n regions. (E) ISH with a digoxigenin-labeled perlecan domain V sense probe. ISH was performed in groups of two to fi ve samples, and representative images are shown. (H -N) Whole mount immunohistochemistry with an affi nity-purifi ed anti -mouse perlecan antibody. Perlecan can be detected as early as the 64-and 1,000-cell stage of embryonic development (2 and 3 hpf, respectively) throughout the cell mound (I and J). At 1 dpf, perlecan protein (L and M) is detected throughout the head (L, arrow), trunk, and tail and is specifi cally localized to the developing muscle myoseptae (M, arrows) and the developing vasculature. By 2 dpf (N), perlecan protein is specifi cally detected in the trunk vasculature, including the DLAV (N, black arrows) and axial vessels (N, white arrows). (H and K) Immunohistochemistry images in which the primary antibody was omitted. Bars, 500 μ m.
cardiovascular and musculoskeletal systems that became visible at 1 dpf (Fig. S2 A, available at http://www.jcb.org/cgi/content/full/ jcb.200708022/DC1) and became progressively more apparent as development proceeded (Fig. S2 , B -E). At 2 dpf, the morphants displayed a pronounced curvature of the tail and trunk, which could be classifi ed as mild, moderate, or severe twisting of the from the same matings were injected with an equal volume of phenol red/nuclease-free water mixture as a control. Higher morpholino concentrations (5 -10 ng) caused signifi cant lethality, especially for MO-DV; thus, we used 2.5 ng or less of the morpholinos. Both morpholinos produced an identical phenotype > 90% ( n = 358; P < 0.001; 10 independent experiments) with severe defects in the . High magnifi cation view shows thick fi laments surrounded by six thin fi laments (circle in F). In contrast, perlecan morphants induced by either translation-blocking (B) or splice-blocking (C, E, and G) morpholinos show disarray of muscular architecture with loss of fi laments and irregular fi laments traversing the sarcomeres at variable angles (arrows in B and C). Also notice the presence of areas with reduced thin fi laments (asterisks in E) adjacent to more normal-appearing hexagonal structures (E). The sarcoplasmic reticulum (SR) appears to be normal (E). High magnifi cation of the area labeled by the asterisk in E shows abnormal arrangement of thin and thick fi laments (circle in G). Bars, 1 μ m. body ( Fig. 3, A and B ). The morphants exhibited either no escape response or uncoordinated movements in response to tactile stimuli and often swam in a circular fashion (Video 1).
To further corroborate the specifi city of the morpholinoinduced perlecan phenotype, we used an additional splicingblocking morpholino-targeting domain III (MO-DIII; Fig. 1 A ) . The phenotype evoked by MO-DIII was identical to that evoked by MO-DI and MO-DV ( Fig. 3 C ) . In fi ve independent experiments ( n = 192), MO-DIII injections caused a phenotype in 93 ± 5% of the injected embryos (P < 0.001). To establish that perlecan knockdown was responsible for the developmental anomalies, we purifi ed total RNA from pooled control and MO-DIII -treated embryos ( n = 23 for each group) and performed RT-PCR using two primers fl anking the targeted exon of domain III. The predicted unprocessed RNA induced by MO-DIII would yield a band of ‫ف‬ 300 bp, whereas the processed RNA would yield a band of ‫ف‬ 150 bp. As positive controls, we used cDNA ( In support of the specifi c perlecan knockdown, whole mount immunohistochemistry with the antiperlecan antibody showed a marked suppression of perlecan expression in the morphants ( Fig. 3 , F and G ) as compared with controls ( Fig. 3 E ) . The effects of the three morpholinos phenocopied each other, providing evidence that the observed developmental defects were specifi c for perlecan knockdown. The observed perlecan morphant ' s phenotype does not appear to be the result of developmental delay because we observed the onset of the heart beat and pigment development in all embryos. The morphants also exhibited a progressive dilatation of the pericardial sac in > 90% of the cases. The embryos with the most severe phenotype survived 2 -3 d, whereas the milder phenotype survived up to 7 -9 dpf, at which time all of the morphants expired with severe generalized edema and cardiac failure, as shown by a progressive reduction in ventricular function and contractility.
To further prove the specifi city of the observed perlecan knockdown phenotype, we performed two additional experiments in which we injected MO-DI and a morpholino targeting the p53 gene. The rationale for these studies is based on a recent report that morpholinos can nonspecifi cally activate the p53 gene, causing off-target phenotypic effects that are not caused by the specifi c morpholino used ( Robu et al., 2007 ) . In both experiments, the coinjection of MO-DI and p53 morpholino maintained the MO-DI control and morpholino-treated embryos. The muscular phenotype was evident at 2 dpf with signifi cant loss of myofi laments and disruption of mitochondria (Fig. S3 , available at http://www .jcb.org/cgi/content/full/jcb.200708022/DC1). However, the muscular phenotype became progressively more severe with time. By 5 dpf, control embryos exhibited a well-defi ned muscle structure, with highly organized bundles of myofi bers surrounded by mitochondria and glycogen ( Fig. 5 A ) . In contrast, morphants induced by either translation-or splice-blocking morpholinos showed a marked disarray of muscle fi bers ( Fig. 5, B and C ) . Often, the fi laments appeared to be interwoven, and clear (less electron dense) bands traversed the sarcomeres at a longitudinal angle, whereas the I bands, the clear bands containing the thinner and darker Z bands, were often misaligned and tortuous ( Fig. 5 C ) . In cross sections, control fi laments were assembled in a hexagonal arrangement typical of mature myofi brils, with each thick fi lament (myosin fi laments) encircled by six thin fi laments of actin that are situated at the trigonal positions of the lattice so that each is shared by three equidistant thick fi laments ( Fig. 5, D and F ) . In the perlecan morphants, cross section analysis confi rmed the misalignment and irregular ultrastructure observed in the longitudinal sections. Specifi cally, we found irregular hexagonal arrays and areas in which the thick fi laments were not associated with thin fi laments ( Fig. 5 E ) . Because of the interwoven and twisted nature of the sarcomere, it was difficult to take focused electron micrographs, and, in the few exceptions, the thin fi laments of actin were irregularly aligned with the thick myosin fi laments ( Fig. 5 G ) . Essentially, myofi laments were present but incorrectly oriented. However, the structure of the sarcoplasmic reticulum was fully preserved.
Next, we investigated the distribution of actin-containing fi laments using fl uorescently labeled phalloidin. The morphants phenotype (Fig. S2 F) , further confi rming the specifi city of MO-DI phenotypic effects. Any observed defects in head, brain, or eye development are likely nonspecifi c side effects of MO-DI morpholino because coknockdown with p53-MO did not maintain these phenotypic abnormalities. Additionally, a morpholino standard control oligonucleotide did not induce any phenotype (Fig. S2 F) .
Perlecan is not required for the formation of most basement membranes
Longitudinal sections of the trunk of 4-dpf control zebrafi sh showed a well-formed DA fi lled with red cells and a properly developed PCV ( Fig. 4 A ) . In contrast, in the perlecan morphants, the lumen of the DA was often collapsed and devoid of erythrocytes at 4 dpf ( Fig. 4 B ) , although at earlier time points, the lumen was patent with circulation (see Perlecan is essential for developmental angiogenesis...). In addition, we observed a signifi cant disruption of the muscular architecture in the perlecan morphants, with numerous vacuolizations and nucleated cells indicating muscle regeneration ( Fig. 4 B ) . These lesions were found throughout the entire myotome, suggesting an essential role for perlecan in muscle development and maintenance. Ultrastructural analysis of various basement membranes, including vessels, skin, and notochord, showed no signifi cant alterations in the morphants ( Fig. 4, C -I ), which is in agreement with the perlecan-null mice in which basement membrane assembly is developmentally normal ( Arikawa-Hirasawa et al., 1999 ; Costell et al., 1999 ) .
Loss of perlecan causes an unexpected severe myopathy
To understand the effects of perlecan knockdown on muscle patterning, we performed a detailed ultrastructural analysis of the vascular markers of vascular cell fate and specifi cation ( Carmeliet, 2005 ) . Thus, in both transgenic fi sh, there is an endothelial-specifi c expression of gfp , thereby allowing continuous in vivo observation of vertebrate embryonic vascular development.
In contrast to the axial vessels, DA and PCV, the ISVs and parachordal vessels develop through angiogenesis ( Childs et al., 2002 ) . The ISVs are the primary sprouts emerging from the DA at ‫ف‬ 1 dpf. They are partially patent by 1.5 dpf and fully functional by 2 dpf ( Isogai et al., 2003 ) . The ISVs follow a pattern that is independent from circulation and is tightly regulated by spatially and temporally defi ned genetic cues ( Childs et al., 2002; Isogai et al., 2003 ) . As the growing ISVs approach the dorsolateral roof of the neural tube, they divide into two major branches that turn caudally and rostrally to form the DLAVs ( Isogai et al., 2001 ( Isogai et al., , 2003 . The secondary angiogenic sprouts emerge exclusively from the PCV and develop into the primary vascular network. The parachordal vessels, which are positioned along the horizontal myoseptae at either side of the notochord, arise by angiogenic growth of secondary sprouts from the PCV ( Isogai et al., 2003 ) . The perlecan morphants showed relatively well-developed axial vessels but exhibited signifi cant suppression of ISVs as compared with control embryos ( Fig. 7 , A -D ). At 2 dpf, the ISVs were only partially formed, and the DLAVs were not formed at all in the most severe phenotypes induced by the translation-blocking morpholino MO-DI. The sprouts exhibited a reduced protrusive activity and were very thin and blunt ended. The endothelial cells often did not completely migrate along the myoseptae from the DA ( > 90%; n = 287 in six separate experiments) and followed abnormal paths failing to interconnect. In most cases, the ISV stopped at the level of the notochord ( Fig. 7 , B and D ) and failed to form the regular lattice of vessels present on either side of the trunk. At later stages, some ISV sprouts reached the DLAV level, but they did not properly assemble these vessels, and several misguided vessel branches were noted growing away from the vertical myoseptae (Fig. S4 , available at http://www.jcb .org/cgi/content/full/jcb.200708022/DC1). The persistence of these anomalous vessels at 3 -4 dpf indicates that the phenotype of the perlecan morphants is not the result of just a nonspecifi c developmental delay caused by the morpholino injection. Identical vascular changes were generated by the splice-blocking morpholino MO-DV ( n = 225; six independent experiments; Fig. S5, A -H) .
The perlecan morphants induced in the vegfr2-gfp transgenic zebrafi sh also produced an identical phenotype with a poorly formed angiogenic network (Fig. S5, I -N) . In addition, there was pericardial edema and stretching of the atrium and ventricle, which became more severe with time (Fig. S5, K -N) . Similar results were obtained with the splicing morpholinos MO-DV and MO-DIII (unpublished data). Overall, there was a concurrent reduction in heart beats per minute with a mean of 98 ± 8 for the morphants versus 158 ± 11 for the controls ( n = 24; P < 0.001).
By live DIC videomicroscopy, we observed robust circulation in the control heart, head, and axial vessels as well as the various branches emanating from the DA, PCV, and DLAV (Videos 2 and 4, available at http://www.jcb.org/cgi/content/ full/jcb.200708022/DC1). In contrast, in the most severe phenotype caused by the knockdown of perlecan , we observed no circulation in the head and trunk regions in spite of robust heart contraction (Video 3). In the milder morphant phenotype, exhibited blocky somites, with less defi ned chevron-shaped boundaries and often clear spaces between the muscle fi bers ( Fig. 6 C , arrows) . The muscle bundles were often interwoven, which is better illustrated under differential interference contrast (DIC) microscopy ( Fig. 6 D ) , as compared with the regular array of muscle bundles in the control larvae ( Fig. 6, A and B ) .
Examination of control embryos using polarized light microscopy, a technique used to investigate various muscle mutant zebrafi sh ( Granato et al., 1996 ; Kunkel et al., 2006 ) , revealed that axial muscle was highly birefringent at 2 dpf ( Fig. 6 , E and F ) as a result of the ordered array of myofi laments in striated muscle. In contrast, perlecan morphants showed an overall decrease in birefringence with patchy areas of hypobirefringence, suggesting a severe disruption of the sarcomeric structures ( Fig. 6, G and H ) . Moreover, in the morphants with a moderate phenotype, the chevron-shaped myoseptae were smooth and u shaped ( Fig. 6, I and J ) .
Next, we studied the muscular expression of acetylcholine esterase (AChE) and its receptor (acetylcholine receptor [AChR]) in control and morphant embryos. The rationale for these studies is based on the fact that a set of molecules, including AChE, AChR, perlecan, and dystroglycan, cluster at the neuromuscular junction, where muscle contraction is initiated ( Rotundo, 2003 ) . The collagen-tailed form of AChE is highly expressed in the innervated regions of skeletal muscle fi bers and is attached to the synaptic basement membrane. It has been shown that perlecan is essential for targeting of the collagen-tailed form of AChE to the neuromuscular junction ( Arikawa-Hirasawa et al., 2002 ). We used whole mount zebrafi sh embryos at 4 dpf and two toxins, AlexaFluor488-labeled fasciculin (green) and AlexaFluor555-labeled ␣ -bungarotoxin (red), to label AChE and AChR, respectively. In control zebrafi sh trunk, AChR was distributed as a fi ne array along the fi bers and at myoseptal junctions ( Fig. 6 K ) , whereas AChE labeling was diffuse with focal clustering at the myoseptal junctions ( Fig. 6 L) . The perlecan morphants displayed a marked reduction and mislocalization of AChR, and short clusters of AChE were detected at the myoseptal junctions, often with skipping of somites ( Fig. 6 M ) . In the most severe morphants, AChR clustered to intersomitic septae ( Fig. 6 N ) , with the somites mostly devoid of AChR.
Collectively, our fi ndings indicate that perlecan is essential for the development and integrity of somitic muscle and suggest a relationship between AChR and perlecan. The lesions were found throughout the entire myotomes, demonstrating an essential role for perlecan in skeletal muscle development and maintenance. The loss and misalignment of myofi laments could potentially induce abnormal and uncoordinated movement. This could provide a plausible explanation for twisting of the body and tail and for the circular swimming observed in the perlecan morphants with severe phenotypes (Video 1).
Perlecan is essential for developmental angiogenesis and cardiovascular function
To monitor vascular development, we used two transgenic zebrafi sh expressing gfp under the guidance of either the fl i1 or vegfr2 promoter ( Cross et al., 2003 ) . The transcription factor fl i1 and vegfr2/fl k1 are two endodermal morphants showed a marked reduction in alkaline phosphatase staining of the head and axial vessels and a total absence of SIV labeling ( Fig. 7, G -J ) . The profound effects of perlecan knockdown on endothelial cell alkaline phosphatase activity suggests that the vascular changes are not secondary to abnormal somitic muscle development but are specifi c for endothelial cells, further proving the signifi cant effects of perlecan defi ciency on developmental angiogenesis. We conclude that perlecan is essential for both robust migration of the primary endothelial sprouts and for maintaining the path of these vessels along the vertical myoseptae.
we saw regular blood fl ow through the axial vessels but a greatly diminished or absent circulation in the ISVs and DLAVs (Videos 5 and 6). These results indicate that the disrupted or malformed ISVs and DLAVs are not functionally patent in the perlecan morphants.
Next, we examined endogenous alkaline phosphatase activity as a marker enzyme for the developing vasculature. In control embryos, the endogenous alkaline phosphatase activity labeled the major cerebral and axial vessels as well as the subintestinal vessels (SIVs), which develop by angiogenesis from the DA at ‫ف‬ 3 dpf ( Fig. 7, E and F ) . In contrast, all MO-DI preparations is shown in Fig. 8 A . Embryos were injected with 2.5 ng MO-DI and were randomized into two groups. Half of the embryos received phenol red, whereas the other half received 10 ng perlecan or domain V/endorepellin. A signifi cant rescue of the twisted body phenotype (ranging between 66 and 82%; n = 29 for perlecan and n = 36 for endorepellin) was achieved by coinjection of full-length perlecan or endorepellin. The rescue of the phenotype was quite striking, and several zebrafi sh survived up to larval stage ( Fig. 8, B and C ) . Notice that the effects of the morpholinos in the rescued morphants are still visible, including slightly bent tails and moderate pericardial edema ( Fig. 8, B and C ) , indicating that perlecan and endorepellin were capable of rescuing the phenotype, at least partially. Collectively, these fi ndings complement the immunohistochemical data, corroborate the specifi city of our antisense strategy, and support a key role for perlecan and endorepellin in maintaining cardiovascular and musculoskeletal function.
Rescue experiments using human perlecan and endorepellin
Conclusive determination of any phenotype is generally made through targeting of the same gene at several nonoverlapping sites using antisense morpholinos or by RNA/protein rescue. Given the large size of perlecan mRNA (predicted mRNA of ‫ف‬ 12 kb), rescue of the morphant phenotype by the overexpression of cRNA encoding full-length zebrafi sh perlecan would be technically impractical. Because of the high degree of homology between human and zebrafi sh perlecan, we chose to inject human perlecan or endorepellin. The former was immunopurifi ed from human coronary artery endothelial cells using an affi nity column coupled with antiperlecan monoclonal antibody ( Whitelock et al., 1999 ) , whereas the latter was purifi ed from the media conditioned by human embryonic kidney 293 -Epstein-Barr virus nuclear antigen cells stably expressing domain V/endorepellin ( Mongiat et al., 2003 ) . The purity of the two mutation in AChE ( ache ; Behra et al., 2002 ) shows a muscular phenotype similar to that of the perlecan morphants, further stressing the role of AChE in generation of the myopathy.
The muscular phenotype evoked by blocking perlecan expression is similar to that observed in the sapje mutant, in which expression of the zebrafi sh orthologue of the X-linked human Duchenne muscular dystrophy, dystrophin, is absent . The overall loss of myofi laments and muscle architecture of the sapje mutant is similar to the ultrastructural appearance of the perlecan morphant skeletal muscle (see Fig. 6 C of . In the sapje mutants, however, the sarcomeres often collapse as a result of their detachment from the myoseptae, a process that leads to enhanced fi ber death. We did not detect any clear muscle detachment in the perlecan morphants, suggesting that other factors are involved in this process.
The absence of dystrophin caused by either a mutation in exon 4 of the dystrophin gene in sapje mutants or by antisense morpholino ( Guyon et al., 2007 ) leads to destabilization of the dystrophin-associated protein complex analogous to what is observed in mammals. A similar muscular phenotype was observed by knockdown of other members of the dystrophin-associated protein complex, including dystroglycan ( Parsons et al., 2002 ) and ␦ -sarcoglycan ( Guyon et al., 2005 ) . Domain V/endorepellin binds with high affi nity to ␣ -dystroglycan ( Talts et al., 1999 ) , and posttranslational or genetic disruption of dystroglycan function also disrupts perlecan binding to dystroglycan ( Kanagawa et al., 2005 ) . Moreover, perlecan and dystroglycan act at the basal side of the Drosophila follicular epithelium to maintain epithelial organization ( Schneider et al., 2006 ) . Collectively, these data suggest that perlecan is a component of a trimolecular complex (laminin -perlecan -dystroglycan) whose disruption could be involved in the pathogenesis of glycosylationdefi cient muscular dystrophy ( Kanagawa et al., 2005 ) . Domain V/ endorepellin interacts with nidogen, fi bulin-2, and collagens IV and XVIII in basement membranes ( Iozzo, 2005 ; Knox and Whitelock, 2006 ) , and interaction of skeletal muscle cells with collagen IV is mediated by cell surface -associated perlecan ( Villar et al., 1999 ) . Thus, perlecan reduction or absence during development could lead to abnormal cell matrix interactions.
Our fi ndings indicate that perlecan might be directly involved in muscular dystrophy, and, although perlecan mutations have been implicated in causing Schwartz-Jampel syndrome characterized by myotonia and chondrodysplasia ( Stum et al., 2006 ; Rodgers et al., 2007 ) , a role for perlecan in the pathogenesis of muscular dystrophy has never been hypothesized before. It will be important to investigate perlecan mutations in humans, especially in patients lacking any mutation in established human causative genes.
A key role for perlecan in developmental angiogenesis and cardiovascular function
Anatomically, vascular development in zebrafi sh proceeds as in other vertebrates ( Isogai et al., 2001 ( Isogai et al., , 2003 Childs et al., 2002 ; . The major axial vessels derive from angioblast migration from the lateral plate mesoderm, whereas secondary vessels form by angiogenesis shortly after coalescence of the angioblasts at the midline. Analogous to
Discussion
In this study, we used a targeted protein depletion approach coupled with protein-based rescue experiments to investigate the role of perlecan in vertebrate development. Perlecan exhibited novel and unique functions in muscle development and angiogenesis. Moreover, similar phenotypes were observed in three distinct genetic backgrounds, including wild type and two transgenic fi sh lines. The perlecan morphants showed a severe myopathy characterized by abnormal orientation and reduced amounts of actin fi laments and disorganized sarcomeres. In the perlecan morphants, primary ISV sprouts initiated but did not completely extend and showed reduced protrusive activity. Essentially, vessels were severely constricted or atretic with reduced or absent functional circulation as clearly documented by live videomicroscopy. Thus, perlecan plays a central role in the complex process of angiogenesis by providing guidance for endothelial cell migration and differentiation as well as branching morphogenesis.
Unexpected role for perlecan in muscular development
In the mouse, perlecan is essential for localizing AChE to the neuromuscular junctions ( Peng et al., 1998 ( Peng et al., , 1999 ArikawaHirasawa et al., 2002; Rotundo, 2003 ) . As the collagen-tailed form of AChE binds directly to perlecan and colocalizes with perlecan and AChR when transplanted onto frozen sections of muscle, it is likely that perlecan is a major acceptor site for AChE at the neuromuscular junctions . This concept is further strengthened by the fact that perlecan binds to ␣ -dystroglycan and that in the absence of ␣ -dystroglycan, neither perlecan nor AChE accumulates at the neuromuscular junctions . Moreover, the cell surface -binding LG domains of muscle agrin and perlecan promote AChR clustering in the presence of laminin-2 ( Smirnov et al., 2005 ) . The perlecan morphants displayed a marked reduction and mislocalization of AChR, and short clusters of AChE were noted at the myoseptal junctions, often with skipping of somites. In the most severe morphant phenotypes, AChR clustered in small regions corresponding to intersomitic septae, with the somites mostly devoid of AChR. We note that in zebrafi sh embryos and larvae, AChE is not clustered as in mammalians and is relatively diffuse in the trunk somites even though the synaptic currents in larvae appears to be mature ( Drapeau et al., 2001 ) . The lesions were found throughout the entire myotomes, demonstrating an essential role for perlecan in skeletal muscle development and maintenance. The severity and progressive myopathy caused by perlecan defi ciency may be partly caused by the fact that zebrafi sh embryonic muscle may not possess the regenerative capacity of mammalian muscle (for review see .
The loss and misalignment of myofi laments could potentially induce abnormal and uncoordinated movement, a plausible explanation for twisting of the body and tail and for the circular swimming. These fi ndings indicate that perlecan is essential for the development and integrity of somitic muscle and suggest a relationship between AChR and perlecan. Notably, a zebrafi sh null
In conclusion, our fi ndings indicate that perlecan functions as a key regulator of somitic muscle development and angiogenesis. This study provides new insights into the biology of this important macromolecule and its C-terminal angiostatic fragment endorepellin and predicts the potential existence of human genetic diseases yet to be characterized in which truncated forms of perlecan might directly affect skeletal muscle and vascular development without causing embryonic lethality.
Materials and methods
Zebrafi sh embryos, perlecan morpholino design, and microinjection Tg (fl i1:egfp) y1 ( Lawson and Weinstein, 2002 ), and Tg (vegfr2: g-rcfp) ( Cross et al., 2003 ) zebrafi sh embryos were maintained according to common practice at ‫ف‬ 28 ° C in embryo medium. Before 24 hpf, embryo medium was supplemented with phenylthiourea to prevent pigmentation. All embryos were housed in the zebrafi sh facility of the Kimmel Cancer Center (Thomas Jefferson University) and were cared for/used in accordance with university Institutional Animal Care and Use Committee guidelines. Between 1 and 10 ng of morpholino antisense oligonucleotides or morpholino standard control oligonucleotide was microinjected into one-to two-cell stage embryos as described previously . Morpholinos (Gene Tools, LLC) were designed to either target the 5 Ј untranslated region/ translation start of zebrafi sh perlecan (MO-DI) or to target a splice junction within perlecan ' s domain III (MO-DIII) or domain V (MO-DV). Perlecan morpholino sequences were as follows: DI-MO, AGTCTTTCAACTCGACCTTCATTCC; DIII-MO, ACGAGTCAACCTGCACAACACACAC; and DV-MO, CATCAAA-CCTGCAAAAGAAAAATGT. The morpholino standard control oligonucleotide sequence was CCTCTTACCTCAGTTACAATTTATA. Morpholino off-target effects were assessed by coknockdown of p53 with a translation-blocking p53MO, GCGCCATTGCTTTGCAAGAATTG, as previously described ( Robu et al., 2007 ) . Gross morphological assessment/phenotypic observations were visualized with a stereomicroscope (MZFIII; Leica) or microscope (Axioplan2; Carl Zeiss, Inc.), which were equipped with a GFP fi lter set for vascularspecifi c analysis in the transgenic embryos, and photographed with a camera (Axiocam; Carl Zeiss, Inc.) and AxioVision software version 3.0.6.1 (Carl Zeiss, Inc.). All embryos were mounted in 3 -4% methylcellulose on glass slides and anesthetized with Tricaine when necessary.
Live imaging and digital microscopy DIC and 3D deconvolved GFP images were collected on a fl uorescent microscope (DM5500 B; Leica) equipped with a camera (DFC340 FX; Leica) and LAS AF version 1.6.1 (Leica) . Live videos with DIC microscopy were captured on the same platform. All video fi les were exported as AVI fi les, which were edited in Vegas Movie Studio version 6.0 (Sony) and rendered in QuickTime Pro version 7.0 (Microsoft). All embryos were mounted in 3 -4% methylcellulose on glass slides and anesthetized with Tricaine when necessary.
Zebrafi sh whole mount immunohistochemistry
Zebrafi sh embryos were fi xed in 4% PFA (Thermo Fisher Scientifi c) in PBS overnight at 4 ° C. Postfi xation embryos were washed three times over 10 min in 1 × PBST (PBS + 0.1% Tween 20), and chorions were removed. Embryos were permeabilized by immersion fi rst in distilled H 2 O for 5 min followed by immersion in ice-cold acetone at Ϫ 20 ° C for 7 min and immersion in distilled H 2 O for 5 min. Embryos were rehydrated in decreasing methanol/PBST series (5 min each in 75, 50, and 25%) followed by washing twice over 3 min in PBST. Blocking was performed for a minimum of 4 h by immersing the embryos in a solution of 0.1 -0.2% BSA (Sigma-Aldrich) at room temperature. Embryos were incubated with the primary antibody, rabbit anti -mouse perlecan, as previously described ( Handler et al., 1997 ) at a 1:250 dilution in blocking solution overnight at 4 ° C. Embryos were washed in blocking solution four times over at least 25 -30 min. Embryos were incubated with the secondary antibody, donkey anti -rabbit HRP (GE Healthcare), at a 1:1,000 dilution in blocking solution for ‫ف‬ 4 h at room temperature. Embryos were washed in blocking solution four times over at least 25 -30 min. Antibody staining was visualized by DAB color development according to the manufacturer ' s instructions (Dako). Staining reactions were terminated by substrate removal and thorough washing in 1 × PBST. Antibody staining was performed on groups of two to fi ve embryos. Embryos incubated with secondary antibody alone served as controls. All embryos were photographed in PBST on an MZFIII stereomicroscope or Axioplan2 microscope with an Axiocam camera and AxioVision software version 3.0.6.1.
perlecan knockdown, suppression of Vegfa by antisense morpholino or VEGF receptor blockade by the small molecule SU5416 ( Cross et al., 2003 ) inhibits ISV formation and causes pericardial edema. These data suggest that the pathology caused by the knockdown of perlecan or VEGFA is caused by an aberrant vascular system rather than by nonspecifi c effects.
Using two transgenic lines of zebrafi sh expressing gfp driven by the promoter of fl i1 , an ETS domain transcription factor specifi c for cells of the hemangioblastic lineage, or vegfr2/ fl k1 , the major receptor for VEGF, we showed that perlecan was not required for endothelial cell differentiation and vasculogenesis. However, perlecan knockdown caused a marked reduction in circulating blood cells in the most severe phenotypes, suggesting a potential role for perlecan in the establishment of angioblast differentiation and lineage. Perlecan morphants showed a marked impairment in the ability of vegfr2/fl i1 -expressing endothelial cells to migrate along the intersomitic septae and form arterio-venous channels. The live videomicroscopy analysis clearly showed a wide spectrum of vascular changes ranging from a reduced to a complete lack of circulatory cells in the ISV, DLAV, and SIV. Disruption of ISV and SIV by knockdown of perlecan is particularly interesting because these vessels develop by angiogenic sprouting, a process that closely resembles tumor angiogenesis. Notably, antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo ( Aviezer et al., 1997 ; Sharma et al., 1998 ) .
We do not know whether the abnormal endothelial cell migration and pathfi nding is caused by a structural role, abnormal signaling of molecules involved in angiogenesis, or a combination of both. Ultrastructural analysis of vascular, epithelial, and notochord basement membranes revealed no signifi cant abnormalities in the perlecan morphants, which is in keeping with the fi ndings of the perlecan-null mouse ( Arikawa-Hirasawa et al., 1999 ; Costell et al., 1999 ) . We favor the possibility that part of the vascular phenotype in the perlecan morphants is caused by abnormal signaling events mediated by hedgehog ( hh ) and Vegf proteins and their receptors ( Covassin et al., 2006 ) .
Perlecan regulates signaling via protein -protein and proteincarbohydrate interactions ( Iozzo, 1998 ) , and recent evidence indicates that perlecan regulates shh signaling during development ( Park et al., 2003 ) and cancer ( Datta et al., 2006a , b ; Lindner et al., 2007 ) . In zebrafi sh embryos, Hh is secreted by the midline structures (fl oor plate, notochord, and hypochord) and is at the top of the signaling cascade controlling vasculogenesis, which also includes vegf and notch ( Lawson et al., 2001 . Moreover, Hh is not only required for adult blood stem cell formation and for the expression of artery-specifi c genes by aortic endothelial cells but is also required for angiogenic sprouting of primary ISV ( Gering and Patient, 2005 ) . Interestingly, Hh is essential for endothelial chord and tube formation in avian and murine embryos ( Vokes et al., 2004 ) , suggesting that its role in vasculogenesis is conserved in vertebrate embryos. Thus, a plausible scenario is that during somitogenesis and vasculogenesis, Hh activity is perturbed by the lack of perlecan, which might also affect the vegf -vegfr2 axis as well as other potential players such as the fgf -fgfr signaling pathway.
RT-PCR
Zebrafi sh total RNA ( n = 23 embryos per group for morpholino verifi cation experiment; n = 40 embryos per group for developmental analysis) was isolated according to the TRIZOL method (Invitrogen). For reverse transcription, total RNA was annealed with Oligo(dT) primer (Roche) at 70 ° C for 5 min followed by the addition of 5 × Moloney murine leukemia virus buffer (Thermo Fisher Scientifi c), 10 mM deoxynucleotide triphosphates (Thermo Fisher Scientifi c), RNAsin (Promega), Moloney murine leukemia virus reverse transcription (Thermo Fisher Scientifi c), and incubation at 42 ° C for 1 h. Reverse transcription reactions were heated at 90 ° C for 10 min followed by incubation at 4 ° C for 2 min before usage, or reactions were kept at 4 ° C for prolonged cDNA storage. Perlecan domain III PCR reactions contained cDNA, 10 × PCR buffer (Thermo Fisher Scientifi c), 10 mM deoxynucleotide triphosphates (Thermo Fisher Scientifi c), 10 pmol/ l DIIIF primer ' GCTAGTGGATCTGTCTCG ' , and 10 pmol/ l DIIIR primer ' CTCCTCGCTGAAGTGAGT ' (Invitrogen). PCR reactions were analyzed on 4% agarose gel electrophoresis.
Zebrafi sh endorepellin riboprobe generation and whole mount ISH For endorepellin/domain V riboprobe generation, zebrafi sh perlecan domain V sense/antisense riboprobes were synthesized by in vitro transcription from the TOPO (zebrafi sh domain V) plasmid with Sp6 (Thermo Fisher Scientifi c) or T7 (Promega) RNA polymerase and were digoxigenin labeled via digoxigenin-UTP (Roche) incorporation during the in vitro transcription reaction. For ISH, RNA localization/detection with sense/antisense riboprobes was performed on groups of two to fi ve embryos essentially as described previously ( Childs et al., 2002 ) . All embryos were photographed on an MZFIII stereomicroscope or Axioplan2 microscope with an Axiocam camera and AxioVision software version 3.0.6.1.
Protein rescue
Human perlecan was immunoaffi nity purifi ed from the secretions of human coronary arterial endothelial cells using an affi nity column containing a monoclonal antibody against perlecan protein core ( Whitelock and Iozzo, 2002 ) . Recombinant human endorepellin was purifi ed from 293--EpsteinBarr virus nuclear antigen cells stably transfected with the appropriate vector ( Mongiat et al., 2003 ; Bix et al., 2007 ) . The proteins were diluted to reach a concentration of ‫ف‬ 1 μ g/ l, and 2.5 -4 nl were microinjected into one-to two-cell stage embryos either alone or in combination with antisense morpholino. Table S1, Table S2 , and Fig. S1 show structural analysis of zebrafi sh perlecan and comparative analysis of Danio rerio domain V/endorepellin (TPA BK006379 and GenBank/EMBL/DDBJ accession no. EU379567 ). Fig. S2 shows a comparison of MO-DI and MO-DV perlecan morphants and p53 coknockdown experiments. Fig. S3 shows abnormal skeletal muscle structure at 2 dpf in perlecan morphants. Fig. S4 shows protracted perlecan knockdown effects on vascular development. Fig. S5 shows vascular analysis in Tg (fl i1:egfp) y1 perlecan morphant embryos. Video 1 shows abnormal swimming of p erlecan morphants, and Videos 2 -6 show circulatory analysis through the heart, head, and axial vessels in control and perlecan morphant embryos. Online supplemental material is available at http://www.jcb .org/cgi/content/full/jcb.200708022/DC1.
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